Likes
On November 8, the research group of Professor Xing Da at the School of Biophotonics of SCNU and Laser Life Science key laboratory of the Ministry of Education, published an academic paper in Advanced Science.
Doctoral degree candidate Chang Haocai is the first author, while Professor Xing Da is the sole corresponding author and South China Normal University is the sole research unit. This work was supported by the National Natural Science Foundation of China and the Natural Science Foundation of Guangdong Province, China.
Cancer immunotherapy, has been introduced into clinical practice as a promising and powerful approach. Specific immune response systems can effectively recognize and eliminate tumor cells, and prevent their metastasis and recurrence. The pivotal way to achieve immunotherapy is to acquire the tumor antigens. However, for the majority of tumors, most endogenous tumor antigens are unknown and ineffectively recognized.
With regard to the challenges of inadequate presentation of tumor antigens, lack of pattern‐recognition receptor signaling, limited ability to elicit an immune response of antigens and adjuvants (producing TLR signaling), and lack of immunotherapy in patient‐specific neoantigens, the research team developed an approach to improve cancer immunotherapy that utilizes endogenous antigen‐carrying nanoparticles (EAC‐NPs), which specifically target APCs and subsequently result in enhanced T cell responses and improved anti-tumor efficacy.
(Figure of the paper to explain the theory)
The work using nanotechnology provides a promising strategy in improving anti-tumor immunity by enhancing the immunogenicity and presentation of tumor self‐antigens for cancer immunotherapy. The therapeutic efficacy of endogenous antigen‐carrying nanoparticles (EAC‐NPs) was evaluated in a subcutaneous mastadenoma model and a pulmonary metastatic melanoma model. Importantly, the mechanisms governing the anti-tumor response induced by the nanoparticles were also explored. Therefore, the work of the research team can provide an ideal platform for precision medicine with personalized immunotherapy and practical way cancer treatment.
Link: “Targeting and Specific Activation of Antigen-Presenting Cells by Endogenous Antigen-Loaded Nanoparticles Elicits Tumor-Specific Immunity” <a href="https://doi.org/10.1002/advs.201900069" target="_blank" rel="noopener noreferrer"
Sourced from the School of Biophotonics of SCNU
Translated by Wen Yanyu
Proofread by Edwin Baak
Reviewed by Li Jianru
What to read next:
